Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06632964RecruitingPhase 1
Testing VT-101 for non-muscle invasive bladder cancer
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
Xuzhou, JiangsuAges 18–75 - NCT06635330RecruitingPhase 1/Phase 2
CAR T cell therapy for children with relapsed B-cell leukemia
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
Tehran, Tehran ProvinceAges 2–18 - NCT06637631RecruitingPhase 2
Testing an oral pill for moderate to severe Crohn's disease
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
Sun City, ArizonaAges 18–75 - NCT06638710RecruitingPhase 2
Testing oral midazolam for care in elderly with dementia who refuse care
This trial tests if giving a medication called midazolam by mouth can help older adults with memory problems who refuse care to accept it more calmly. It is for people in certain hospital or long-term care units, with moderate to severe memory loss and a history of resisting care.
Grenoble, IsereAges 60 years+ - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70 - NCT06641895RecruitingEarly Phase 1
Testing BBM-D101 gene therapy for Duchenne muscular dystrophy
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06643130RecruitingPhase 3
Testing a combo treatment for high blood pressure and cholesterol
This study tests whether adding two medications together helps people who have both high blood pressure and high cholesterol. It aims to see if the combination works better and is safe.
SeoulAges 19 years+ - NCT06643416RecruitingPhase 3
Timolol cream for nail problems from lung cancer drugs
This trial tests if a timolol cream can help treat painful or infected nails (paronychia) caused by certain lung cancer medications. If you have non-small cell lung cancer and nail problems from your treatment, this study may offer relief.
Hong KongAges 18 years+ - NCT06643819RecruitingPhase 3
Testing a new blood pressure drug
This trial tests a new combination blood pressure medicine called CKD-202A. It is for adults with high blood pressure who have not had other treatments or conditions that could affect the results.
WŏnjuAges 19 years+ - NCT06646276RecruitingPhase 3
New drug combo vs standard care for first-line extensive-stage small cell lung cancer
This trial tests a new combination of drugs (BMS-986489 with chemotherapy) against the current standard treatment (atezolizumab with chemotherapy) for people who have just been diagnosed with extensive-stage small cell lung cancer. It aims to see which approach works better and is safer.
Daphne, AlabamaAges 18 years+ - NCT06647550RecruitingPhase 2
Testing a new pill for type 2 diabetes not well controlled by diet and exercise
This trial tests a new medication, HD-6277, to see if it can help lower blood sugar in adults with type 2 diabetes that isn't well managed by diet and exercise alone.
SeoulAges 19–75 - NCT06647745RecruitingPhase 3
Study for type 2 diabetes and high blood pressure
This study tests a new combination of three medications (THP-00101, THP-00102, and THP-00103) for people with type 2 diabetes and essential high blood pressure. It aims to see if this combination is safe and effective compared to standard treatments.
SeoulAges 19 years+ - NCT06647888Recruiting
Study of Enavogliflozin for Type 2 Diabetes with High Blood Pressure or High Cholesterol
This study looks at how well a medication called Enavogliflozin works for people with type 2 diabetes who also have high blood pressure or high cholesterol. It aims to see if the drug is safe and effective when taken as part of routine care.
SeoulAges 19 years+ - NCT06650319RecruitingEarly Phase 1
Testing LY-M003 injection for Wilson disease
This study tests an injection called LY-M003 for people with Wilson disease who have already been treated with standard medicines. The goal is to see if it is safe and works for them.
Hangzhou, ZhejiangAges 10–60 - NCT06650852RecruitingPhase 2
A study of 3 drugs for chronic hepatitis B
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
Beijing, Beijing MunicipalityAges 18–60 - NCT06651281RecruitingPhase 3
Long-term safety and effectiveness of tulisokibart for Crohn's or colitis
This study gives tulisokibart to people who already took part in an earlier trial for Crohn's disease or ulcerative colitis and are still benefiting from it. The goal is to see how safe and effective the medicine is over a longer period.
Bristol, ConnecticutAges Any age - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70 - NCT06655662RecruitingPhase 1
Gene therapy for severe beta-thalassemia
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
GuangxiAges 6–35 - NCT06658145Recruiting
New tool for vaginal hysterectomy for fibroids
This trial tests a new tool that helps doctors see better during vaginal hysterectomy (removing the uterus through the vagina). It is for women with uterine fibroids who need this surgery, and aims to see if it is safe and works well.
Beijing, Beijing MunicipalityAges Up to 60 years - NCT06658197RecruitingPhase 3
Comparing a new clot-busting drug for severe stroke
This study tests a medication called tenecteplase, given before a procedure to remove a large blood clot in the brain. It may help people who have had a severe stroke within the last 4.5 hours.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06659653RecruitingEarly Phase 1
PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Jinzhou, HubeiAges 18–70 - NCT06660719RecruitingPhase 3
New stroke medicine SP-8203 with clot-busting therapy
This trial tests a new medicine called SP-8203 added to standard clot-busting treatment for people having a moderate to severe stroke. The goal is to see if it helps improve recovery and is safe.
BusanAges 19–85 - NCT06663137RecruitingPhase 2
Study of a new treatment for high-grade bladder cancer
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
RaananaAges 18–80
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.